Novo Nordisk A/S (LON:0QIU)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 126.70B -59.8% |
| Revenue (ttm) | 36.10B +6.4% |
| Net Income | 11.97B +1.4% |
| EPS | 2.69 +1.8% |
| Shares Out | n/a |
| PE Ratio | 10.59 |
| Forward PE | 11.76 |
| Dividend | 1.32 (0.53%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 499,701 |
| Average Volume | 1,596,054 |
| Open | 249.05 |
| Previous Close | 247.00 |
| Day's Range | 242.50 - 251.65 |
| 52-Week Range | 224.55 - 573.20 |
| Beta | 0.24 |
| RSI | 32.66 |
| Earnings Date | May 6, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Royce Smaller-Companies Growth Fund FY 2025: What Worked
Nine of the portfolio's 10 equity sectors made a positive impact on performance, with Health Care, Industrials, and Materials making the largest positive contributions. Palvella's shares appreciated s...
14 Ideal 'Safer' Dividend Buys From 70 Mid-March Graham Value All-Stars (GVAS)
Top ten large cap value (GASV) stocks are forecasted to deliver an average 38.12% net gain by mid-March 2027, with yields up to 13.03%. Analyst targets suggest the five lowest-priced, highest-yield GA...
Hims & Hers Health And Novo Nordisk: A Corporate Remarriage That May Work Out Profitably
Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate access to lucrative branded GLP-1 therapies. HIMS has demonstrated rapid reve...
Does This Deal Make Novo Nordisk Stock a Buy?
Novo Nordisk will partner with Hims & Hers to sell affordable branded semaglutide. This will decrease competition from compounded versions of the drug.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to ...
Why Hims & Hers Health (HIMS) Stock Is Surging In Thursday's Premarket
Hims & Hers Health Inc (NYSE: HIMS) shares are climbing in Thursday's premarket session. This follows a double-digit gain during Wednesday’s regular trading hours. Novo Nordisk Partnership Boosts Sen...
Novo Nordisk stock slump hits value of controlling shareholder
Novo Nordisk stock slump hits value of controlling shareholder
Novo Nordisk (NVO) Shares Plummet, Impacting Novo Holdings
Novo Nordisk (NVO) Shares Plummet, Impacting Novo Holdings
Novo Holdings announces 2025 Annual Results
Total Income and Investment Returns in 2025 were DKK 21 billion (€2.8 billion). For 2025, Total Income and Investment Returns consisted of Income from dividends from the Novo Group companies (DKK 15 b...
India warns drugmakers against direct or surrogate weight-loss drug and obesity ads
India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could act as surrogate promotion...
Hims & Hers Health Stock Is Surging Wednesday: What's Going On?
Hims & Hers Health Inc (NYSE: NVO) shares are higher Wednesday after a series of announcements this week reinforced investor optimism. ... Full story available on Benzinga.com
This Novo Nordisk Partnership Shows That HIMS Has All The Leverage
Hims & Hers (HIMS) is still a Strong Buy, given that the transformative partnership with Novo Nordisk resolves legal risks and unlocks new growth avenues. HIMS' core value lies in its 2.5M+ cash-pay c...
Health Rounds: Death from dementia on the rise among people with type 2 diabetes
In people with type 2 diabetes in the world's richest countries, deaths from cardiovascular disease are declining while mortality from dementia is on the rise, a large analysis has found.
Ozempic Maker Novo Nordisk Faces Another Strike By US FDA With Warning Letter Over 'Systemic Failures' In Safety Reporting
The U.S. Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk A/S (NYSE: NVO), marking another regulatory strike on the pharmaceutical giant over the last six months followi...
FDA sends warning letter to Novo Nordisk over failure to report deaths, adverse side effects of GLP-1s
The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, p...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised...
Asset Manager Exits Shares of Hims & Hers Health
Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk.
Hims & Hers Stock Upgraded After Novo Nordisk Agreement. Why It Isn’t a Buy Yet.
What's Fueling The Rise In Hims & Hers Health Stock Today?
Hims & Hers Health Inc (NYSE:HIMS) shares are rising higher on Tuesday. Multiple analysts upgraded the stock following the company's deal with Novo Nordisk this week.
Novo Nordisk (NVO) Warned by FDA Over Reporting Lapses
Novo Nordisk (NVO) Warned by FDA Over Reporting Lapses
FDA Warns Novo Nordisk Over Potential Unreported Ozempic Side Effects, Deaths
Weight loss drug giant Novo Nordisk has received a warning letter from the U.S. Food and Drug Administration for failing to report side effects potentially linked to Ozempic usage, including two death...
Novo Nordisk Warned by FDA Over Adverse Event Reporting
Novo Nordisk Warned by FDA Over Adverse Event Reporting
FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients
The FDA underscored cases including two deaths and a suicide linked to patients taking semaglutide, which Novo markets as Ozempic and Wegovy.
2 Healthcare Stocks That Are Too Cheap to Ignore
Pfizer and Novo Nordisk are trading at (more than) reasonable levels given their underlying strengths. Both drugmakers could make pipeline progress that will allow them to improve their financial resu...
Relative Strength Alert For Novo-Nordisk
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important ...